CompletedNot Applicable

Zephyr Etude Post-Inscription (French Registry)

France155 participantsStarted 2021-01-04

Plain-language summary

The objective of this Registry is to provide ongoing safety and effectiveness assessment of the Zephyr Valve treatment of adult patients with Chronic Obstructive Pulmonary Disease (COPD) Grade III and Grade IV in order to support the renewal of the inscription of the Zephyr Valve on the list LPPR (Art 165-1) in France.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with emphysema (COPD Grade III and Grade IV) considered appropriate for the bronchoscopic lung volume reduction procedure by the physician. * Subjects who signed an Informed Consent Form to allow data collection. Exclusion Criteria: * Subjects determined to have collateral ventilation between the target(s) and ipsilateral lobe(s).

What they're measuring

Forced Expiratory Volume in 1 second (FEV1)

Timeframe: 12 months

Trial details

NCT IDNCT04517916

SponsorPulmonx Corporation

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2022-06-22

View on ClinicalTrials.gov More Emphysema or COPD trials